Skip to main content
Kao-Ping Chua, MD, Pediatrics, Ann Arbor, MI

Kao-PingChuaMDPhD

Pediatrics Ann Arbor, MI

Associate Professor of Pediatrics, University of Michigan Medical School

Dr. Chua is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Chua's full profile

Already have an account?

  • Office

    2800 Plymouth Road
    NCRC Building 16, SPC 2800, Room G026W
    Ann Arbor, MI 48109
    Phone+1 734-615-8169

Education & Training

  • Harvard University
    Harvard UniversityPh.D., Health Policy, 2011
  • Boston Children’s Hospital/Boston Medical Center
    Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2007 - 2010
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 2007

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2017 - 2027
  • IL State Medical License
    IL State Medical License 2015 - 2020
  • MA State Medical License
    MA State Medical License 2010 - 2017
  • Pediatrics
    American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Academic Pediatric Association Young Investigator Award, 2016

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Estimates from Heterogeneous Studies of Opioid-Related Morbidity  
    Kao-Ping Chua, MD, JAMA Pediatrics
  • Potential Change in Insulin Out-of-Pocket Spending Under Cost-Sharing Caps Among Pediatric Patients with Type 1 Diabetes  
    Kao-Ping Chua, MD, JAMA Pediatrics
  • Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients with Type 1 Diabetes  
    Kao-Ping Chua, MD, JAMA Internal Medicine
  • Join now to see all

Authored Content

  • Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19August 2020
  • Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19August 2020
  • Out-of-Pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014October 2018
  • Effect of FDA Investigation on Opioid Prescribing to Children After Tonsillectomy/AdenoidectomyDecember 2017
  • Effect of FDA Investigation on Opioid Prescribing to Children After Tonsillectomy/AdenoidectomyNovember 2017
  • Join now to see all

Press Mentions

  • Obtaining ADHD Drugs via Telehealth Could Increase Addiction Risk
    Obtaining ADHD Drugs via Telehealth Could Increase Addiction RiskMarch 5th, 2025
  • Kennedy Thrusts Antidepressants into the Spotlight as Doctors and Advocates Defend Them
    Kennedy Thrusts Antidepressants into the Spotlight as Doctors and Advocates Defend ThemFebruary 21st, 2025
  • Stimulant Prescriptions Rebound to Pre-Pandemic Levels for Girls, Not Boys
    Stimulant Prescriptions Rebound to Pre-Pandemic Levels for Girls, Not BoysFebruary 4th, 2025
  • Join now to see all

Grant Support

  • Insurance-related barriers to medications for opioid use disorder in private and Medicaid plansUNIVERSITY OF MICHIGAN AT ANN ARBOR2022–2026
  • Evaluating Policy Interventions to Decrease Excessive and Risky Perioperative Opioid PrescribingUNIVERSITY OF MICHIGAN AT ANN ARBOR2022–2026
  • Using Default Opioid Prescription Settings to Limit Excessive Opioid Prescribing to Adolescents and Young AdultsNational Institute on Drug Abuse2019–2024

Professional Memberships